Alpha-galactoside-containing oligosaccharides and glycosphingolipids (Gb3/GL-3)

Alpha-galactoside-containing oligosaccharides and glycosphingolipids are a diverse group of carbohydrate-conjugated molecules characterized by terminal alpha-linked galactose residues. The most clinically significant member is globotriaosylceramide (Gb3, also known as GL-3 or ceramide trihexoside), which is a major component of mammalian cell membranes and serves as the primary receptor for Shiga toxins produced by certain bacteria [1, 2]. In healthy individuals, these molecules are degraded in the lysosome by the enzyme alpha-galactosidase A [1]. However, a deficiency in this enzyme leads to Fabry disease, a progressive lysosomal storage disorder where the systemic accumulation of these lipids causes damage to the vascular endothelium, kidneys, heart, and nervous system [3, 6]. Beyond metabolic disorders, the alpha-gal (Gal-alpha-1,3-galactose) epitope is a potent antigen in humans, who naturally possess high titers of anti-Gal antibodies [5]. This interaction is the primary cause of hyperacute rejection in pig-to-human xenotransplantation and is the basis for alpha-gal syndrome, a unique IgE-mediated allergy to red meat triggered by tick bites [4]. Therapeutic interventions focus on reducing the burden of these molecules through enzyme replacement therapy (ERT), substrate reduction therapy (SRT), or pharmacological chaperones that enhance endogenous degradation [3, 6].

Other names

GlobotriaosylceramideGb3GL-3Ceramide trihexosideAlpha-gal antigensGal-alpha-1,3-GalAlpha-galactosyl conjugates

Enzymatic hydrolysis of terminal alpha-galactose residues; inhibition of glycosphingolipid biosynthesis; pharmacological chaperoning of alpha-galactosidase A